Anika Therapeutics (ANIK) Non-Current Deferred Tax Liability (2010 - 2023)

Anika Therapeutics (ANIK) has 14 years of Non-Current Deferred Tax Liability data on file, last reported at $2.0 million in Q3 2023.

• Non-Current Deferred Tax Liability for Q3 2023 came in at $2.0 million, down 71.25% year-over-year; the trailing twelve-month figure through Sep 2023 was $2.0 million (down 71.25% YoY), and the FY2022 annual result was $6.4 million, down 36.63% from the prior year.
• Non-Current Deferred Tax Liability slipped to $2.0 million in Q3 2023 per ANIK's latest filing, from $3.2 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $16.0 million in Q1 2020 and troughed at $2.0 million in Q3 2023.
• A 5-year average of $8.4 million and a median of $8.2 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2020 and 2023: Non-Current Deferred Tax Liability jumped 373.14% in 2020, then sank 71.25% in 2023.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $4.3 million in 2019, then soared by 174.65% to $11.9 million in 2020, then retreated by 14.61% to $10.2 million in 2021, then slumped by 36.63% to $6.4 million in 2022, then slumped by 69.62% to $2.0 million in 2023.
• Business Quant data shows ANIK's Non-Current Deferred Tax Liability at $2.0 million in Q3 2023, $3.2 million in Q2 2023, and $4.1 million in Q1 2023.